Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Healthcare Business Review
Thank you for Subscribing to Healthcare Business Review Weekly Brief
An anhydrous base offers many benefits to compounding pharmacies," PCCA Chief Scientific Officer Gus Bassani said.
By
Healthcare Business Review | Friday, February 03, 2023
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
With SuspendIt Anhydrous, a patent-pending oral suspending vehicle, compounding pharmacies can offer longer BUDs for compounding agents, offering improved physical characteristics, as well as a low water activity technology platform.
FREMONT, CA: "An anhydrous base offers many benefits to compounding pharmacies," PCCA Chief Scientific Officer Gus Bassani said. "There's no water to support the growth of micro-organisms or cause hydrolytic degradation of an API and it opens the potential for formulations to be assigned longer beyond-use dates (BUDs). But what makes our new base really unique is its self-emulsifying properties. This self-emulsifying system improves the miscibility and dispersibility of formulations in aqueous environments and may improve API solubility as well."
Suitable for APIs or other compounds that have incompatibilities with existing aqueous vehicle systems, SuspendIt Anhydrous is PCCA's innovative new oral suspending base.
A majority of the anhydrous bases available on the market are oil-based; however, some patients, particularly children, dislike the taste of oil-based bases and the oily residue they leave behind.